EBMT NEWSLETTER | September 2017 | Volume 58 - Issue 4

EBMT
Important dates
The recent approval of autologous CAR T cells for the treatment of acute lymphoblastic leukemia is a true revolution in the fields of haematology and oncology. Scientifically, we have never been in a better position to advance treatments in life-threatening diseases. Basic and translational research fuelled in recent years by the tools of molecular biology and genomics, has generated unprecedented knowledge. We now can manipulate and genetically engineer many of the cellular effectors that can allow for long-term disease control and cure. And increasingly, we know how to personalize therapy to the unique genetics of the tumor, and the patient. All of these modern approaches will require an increased investment in education and dissemination of knowledge.

The second EBMT International Transplant course (EBMT-ITC) took place in Barcelona on 8-10 September 2017. This event was a great success attracting participants from all over the world. Beside the location, everybody enjoyed the amazing cases reports presented by junior colleagues after each seminal lecture. Based on the feedback we received, it is now clear that the EBMT-ITC has become a major event to disseminate knowledge, and advance education in the fields of stem cell transplantation and cellular therapy. This is part of our continuous commitment to quality of care, modern education and therapeutic innovations.

Mohamad Mohty
EBMT President




Interview with Juliana Bastos, one of the case presenter

Junior doctor in the department of haematology at the Saint-Antoine Hospital, Paris, France

Case presentation: Interstitial Pneumonitis in a patient receiving an HLA-identical sibling transplantation for refractory Hodgkin disease and previous PD1 inhibitor treatment

The second EBMT International Transplantation Course was a high level educational course providing a comprehensive review of the major topics concerning hematopoietic stem cell transplantation, from pre-transplant considerations to early and long-term complications. Transplantation was also discussed in the particular setting of a wide spectrum of hematologic diseases, highlighting the state of the art, recent advances, actual questions and future perspectives. Significant attention was given as well to the new and emerging immunotherapies and cellular therapies and the integration of this evolving knowledge in the field of HSCT, which, from a personal point of view, was a highly interesting topic of discussion in this 2nd ITC. All seminal lectures provided not only a comprehensive scientific review of each theme but also a practical component, from a clinical point of view, with a constant concern on the improvement of the quality of care and quality of life of transplanted patients. Furthermore, all lectures by the experts were followed by a clinical case presentation by a young physician which allowed an open discussion of daily life practice and challenging situations. For us, young physicians, it is certainly a privileged opportunity to widen our knowledge in this area, through the lectures, the discussions with experts and from the shared experiences.  Therefore, I hope the EBMT may continue to provide this learning platform and I would strongly encourage my colleagues to attend and participate in future editions of this EBMT International Transplantation Course.

 
Bookmark and Share